Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
用于高内涵药物测试和精准医学的新生儿肠道芯片平台
基本信息
- 批准号:10674890
- 负责人:
- 金额:$ 60.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAffectAutomobile DrivingBacterial TranslocationBiological ModelsBiopsyCause of DeathCell DeathCellsChildhoodClinicalCoculture TechniquesDataDevelopmentDevicesDiseaseDoseDrug ScreeningEndothelial CellsEndotheliumEnvironmentEpithelial Cell ProliferationEpithelial CellsEpitheliumExcisionFailureFunctional disorderGastrointestinal DiseasesGenetic TranscriptionGenomeGoalsHumanHypermethylationImmuneImmune responseImpairmentIn VitroInfantInflammatoryInflammatory ResponseInflammatory Response PathwayIntestinal DiseasesIntestinesKnowledgeLibrariesMetadataMethodsMethylationMicrofluidic MicrochipsModelingMorbidity - disease rateMucous body substanceNecrotizing EnterocolitisNeonatalOperative Surgical ProceduresOrganoidsPathogenesisPathogenicityPatientsPeristalsisPharmaceutical PreparationsPhenotypePhysiologicalPre-Clinical ModelPreclinical TestingPredispositionPremature InfantPremature Infant DiseasesProcessProductionResearchRoleSafetyScientistSpecimenStretchingSupportive careSurgeonSystemTestingTherapeuticTight JunctionsToxic effectVillusantimicrobialbiobankbisulfite sequencingcell injurycostcost effectivecytokinedesigndrug discoverydrug testingdysbiosisefficacy evaluationepigenomicsgenome-widehigh risk infanthuman diseasein vitro Modelinnovationinsightintestinal epitheliummicrobialmicrobiomemicrobiome componentsmicrobiotamicrophysiology systemmortalitymultidisciplinarymultiple omicsnovelnovel therapeutic interventionnovel therapeuticspatient populationpre-clinicalprecision medicineprematurepreventproteomic signatureregenerativescreeningtherapeutic candidatetherapeutic evaluationtooltranscriptomics
项目摘要
Project Summary/Abstract
The goal of this proposal is to investigate the role of a human microphysiologic intestine-on-a-chip platform as a
precision medicine tool to model a devastating disease affecting premature infants known as necrotizing
enterocolitis (NEC). We developed preclinical models of NEC using both organoids and a “NEC-on-a-chip” model
system to recapitulate the intestinal environment of the human disease in vitro, gain new insights into disease
pathogenesis and test the functional and clinical utility of our models to evaluate the efficacy of candidate
therapeutics. Our NEC-on-a-chip model utilizes a combination of premature infant intestinal organoids along with
human endothelial cells and patient-derived microbiota, to recreate critical aspects of premature gut
pathophysiology. Our preliminary studies demonstrate that co-culture of these components on intestine-on-a-
chip microfluidic devices produces clinical features seen in human NEC such as gut barrier failure with the
breakdown of cellular tight junctions, decreased epithelial cell proliferation, a dramatic increase in the pro-
inflammatory cytokine response, as well as a significant amount of cell death. In this proposal, we will use several
multi-omic approaches to characterize our NEC-on-a-chip model and compare to the human NEC phenotype.
To achieve this, we developed a multi-center NEC Biorepository, which consists of detailed clinical metadata
corresponding to a plethora of human specimens, including intestinal organoids cultured from the biopsies of
premature infants with or without NEC. Furthermore, we have created a high-throughput and high-content drug
screening platform using premature intestinal organoids to identify drugs or compounds that inhibit the
pathogenic inflammatory responses seen in vitro. Moreover, we will demonstrate the functional and clinical utility
of our patient-derived NEC-on-a-chip model as a precision medicine platform to test the dosing, efficacy, and
toxicity of candidate therapeutics. To successfully complete these studies, we established a multi-disciplinary
team with the expertise of a Neonatologist, Cell Biologist, Pediatric Surgeon, Genome Scientist and
Bioinformatician. Taken together, these studies will make a significant conceptual advance in our understanding
of the multicellular interactions with the microbiome of the developing premature intestine and provide new model
systems and preclinical platforms by which the identification and testing of therapeutics for NEC and other
intestinal diseases can be performed in this vulnerable patient population.
项目摘要/摘要
这项提议的目标是调查人类微生理芯片上的肠平台作为
一种精确的医学工具,用于模拟一种称为坏死性早产儿的破坏性疾病
小肠炎(NEC)。我们使用有机化合物和“芯片上的NEC”模型开发了NEC的临床前模型。
系统在体外概括了人类疾病的肠道环境,对疾病有了新的见解
并测试我们的模型的功能和临床实用性,以评估候选的疗效
治疗学。我们的NEC芯片上模型利用了早产儿肠道器官和
人内皮细胞和患者来源的微生物区系,以重建早产儿肠道的关键方面
病理生理学。我们的初步研究表明,这些成分在肠-on-a-a上的共培养
芯片微流控设备可产生人类NEC的临床特征,如肠道屏障功能障碍
细胞紧密连接破裂,上皮细胞增殖减少,细胞内亲和力显著增强。
炎性细胞因子反应,以及大量细胞死亡。在这个提案中,我们将使用几个
多组学方法来描述我们的芯片上NEC模型,并与人类NEC表型进行比较。
为了实现这一点,我们开发了一个多中心NEC生物信息库,它包含详细的临床元数据
与过多的人类样本相对应,包括从猪的活检组织中培养的肠道器官
患有或不患有NEC的早产儿。此外,我们还创造了一种高通量和高含量的药物
使用未成熟的肠道有机化合物进行筛选的平台,以识别抑制该过程的药物或化合物
在体外可见致病性炎症反应。此外,我们还将展示其功能和临床应用。
将我们患者衍生的NEC芯片模型作为精密医学平台,以测试剂量、疗效和
候选治疗药物的毒性。为了顺利完成这些研究,我们建立了一个多学科的
团队拥有新生儿专家、细胞生物学家、儿科外科医生、基因组科学家和
生物信息学家。综上所述,这些研究将在我们的理解上取得重大的概念性进展
多细胞与发育中的早产儿肠道微生物群的相互作用并提供新的模型
用于识别和测试NEC和其他药物的系统和临床前平台
肠道疾病可以在这一脆弱的患者群体中进行。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Stem cells as a therapeutic avenue for active and long-term complications of Necrotizing Enterocolitis.
- DOI:10.1016/j.sempedsurg.2023.151311
- 发表时间:2023-06
- 期刊:
- 影响因子:1.7
- 作者:Fikir M. Mesfin;K. Manohar;W. Shelley;John P. Brokaw;Jianyun Liu;Minglin Ma;T. Markel
- 通讯作者:Fikir M. Mesfin;K. Manohar;W. Shelley;John P. Brokaw;Jianyun Liu;Minglin Ma;T. Markel
Volatile Organic Compound Assessment as a Screening Tool for Early Detection of Gastrointestinal Diseases.
- DOI:10.3390/microorganisms11071822
- 发表时间:2023-07-17
- 期刊:
- 影响因子:4.5
- 作者:Dalis, Costa;Mesfin, Fikir M. M.;Manohar, Krishna;Liu, Jianyun;Shelley, W. Christopher;Brokaw, John P. P.;Markel, Troy A. A.
- 通讯作者:Markel, Troy A. A.
Chondroitin sulfate supplementation improves clinical outcomes in a murine model of necrotizing enterocolitis.
- DOI:10.14814/phy2.15819
- 发表时间:2023-09
- 期刊:
- 影响因子:2.5
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MISTY L GOOD其他文献
MISTY L GOOD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MISTY L GOOD', 18)}}的其他基金
Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
用于高内涵药物测试和精准医学的新生儿肠道芯片平台
- 批准号:
10491072 - 财政年份:2022
- 资助金额:
$ 60.36万 - 项目类别:
Neonatal gut-on-a-chip platform for high content drug testing and precision medicine
用于高内涵药物测试和精准医学的新生儿肠道芯片平台
- 批准号:
10594705 - 财政年份:2022
- 资助金额:
$ 60.36万 - 项目类别:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
坏死性小肠结肠炎甲基化细胞游离 DNA 的无创分析
- 批准号:
10704229 - 财政年份:2021
- 资助金额:
$ 60.36万 - 项目类别:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
坏死性小肠结肠炎甲基化细胞游离 DNA 的无创分析
- 批准号:
10577705 - 财政年份:2021
- 资助金额:
$ 60.36万 - 项目类别:
Non-invasive analysis of methylated cell free DNA in necrotizing enterocolitis
坏死性小肠结肠炎甲基化细胞游离 DNA 的无创分析
- 批准号:
10316733 - 财政年份:2021
- 资助金额:
$ 60.36万 - 项目类别:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
坏死性小肠结肠炎肠道免疫反应的调节
- 批准号:
10543597 - 财政年份:2018
- 资助金额:
$ 60.36万 - 项目类别:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
坏死性小肠结肠炎肠道免疫反应的调节
- 批准号:
10468084 - 财政年份:2018
- 资助金额:
$ 60.36万 - 项目类别:
Modulation of the Intestinal Immune Response in Necrotizing Enterocolitis
坏死性小肠结肠炎肠道免疫反应的调节
- 批准号:
10001502 - 财政年份:2018
- 资助金额:
$ 60.36万 - 项目类别:
Aryl hydrocarbon receptor signaling in the pathogenesis of necrotizing enterocolitis
坏死性小肠结肠炎发病机制中的芳基烃受体信号传导
- 批准号:
9220912 - 财政年份:2017
- 资助金额:
$ 60.36万 - 项目类别:
Novel Anti-Inflammatory Properties of Breast Milk in Necrotizing Enterocolitis
母乳在坏死性小肠结肠炎中的新型抗炎特性
- 批准号:
8820360 - 财政年份:2014
- 资助金额:
$ 60.36万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 60.36万 - 项目类别:
Research Grant